Related Experiment Videos
Suxamethonium and critical illness polyneuropathy
M Hughes1, I S Grant, B Biccard
1Intensive Care Unit, Western General Hospital, Edinburgh, United Kingdom.
Anaesthesia and Intensive Care
|January 13, 2000
Summary
Suxamethonium administration to patients with critical illness polyneuropathy can cause dangerous hyperkalaemia. Many UK intensive care units show a lack of awareness regarding this risk, potentially endangering patient safety.
Area of Science:
- Critical care medicine
- Neurology
- Pharmacology
Background:
- Critical illness polyneuropathy (CIP) is a serious complication in intensive care.
- Suxamethonium, a common muscle relaxant, carries a risk of hyperkalaemia.
- Hyperkalaemia in CIP patients can be life-threatening.
Purpose of the Study:
- To assess awareness of suxamethonium-induced hyperkalaemia risk in UK intensive care units.
- To evaluate clinician knowledge regarding safe drug choices for intubation in CIP patients.
Main Methods:
- A questionnaire was distributed to all UK intensive care units.
- The questionnaire included a clinical scenario of critical illness polyneuropathy.
- Respondents were asked to select drugs for endotracheal intubation.
Main Results:
- 68.7% of respondents selected suxamethonium for intubation.
- 20.4% of respondents opted to avoid muscle relaxants altogether.
- A significant lack of awareness regarding suxamethonium risks in CIP was identified.
Conclusions:
- There is a concerning deficit in the understanding of suxamethonium's dangers in critical illness polyneuropathy.
- This lack of awareness may lead to adverse patient outcomes.
- Further education and guideline reinforcement are necessary for safe practice.